Arcellx Inc
NASDAQ:ACLX
Operating Margin
Arcellx Inc
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Operating Margin Across Competitors
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| US |
A
|
Arcellx Inc
NASDAQ:ACLX
|
4B USD |
-376%
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
-17 527%
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
364.9B USD |
31%
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
157.4B USD |
31%
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
146.5B USD |
38%
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
-370%
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
99.9B USD |
39%
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
113.9B AUD |
26%
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
61.1B USD |
29%
|
|
| US |
|
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
|
59.8B USD |
-7%
|
|
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR |
-33%
|
Arcellx Inc
Glance View
In the bustling landscape of biotechnology, where innovation is the keystone of success, Arcellx Inc. charts an intriguing path. It operates at the cutting edge of medical science, specializing in the development of engineered immunotherapies for the treatment of cancer and other serious diseases. The company's core technology pivots around its proprietary ARC-SparX platform, a modular antibody-recruiting platform designed to enhance the targeting and activation of T-cells against malignant cells. By engineering these immune cells to specifically recognize and attack cancer, Arcellx endeavors to transcend the traditional boundaries of oncology treatment, offering a more personalized and effective therapeutic approach. Arcellx's financial engine is powered by the potential success of its therapies in development, as well as strategic partnerships and licensing agreements. In the biopharma realm, revenue generation often hinges on the successful progression of clinical trials and the eventual approval and commercialization of its products. For Arcellx, this means advancing its pipeline through rigorous clinical phases while also engaging in collaborations with larger pharmaceutical entities. These partnerships not only offer monetary infusions but also extend the reach of Arcellx's innovative therapies, thus amplifying their commercial potential. Through this strategic blueprint, Arcellx positions itself to capture a share of the lucrative oncology market, all while endeavoring to revolutionize patient care through its scientific innovations.
See Also
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Based on Arcellx Inc's most recent financial statements, the company has Operating Margin of -376.3%.
You don't have any saved screeners yet